Core Viewpoint - The company is currently facing potential challenges due to new EU regulations limiting Chinese medical device companies' participation in public tenders valued over 5 million euros, but it has not yet impacted its business in the EU region [3][4]. Group 1: Stock Performance - As of July 18, 2025, the company's stock closed at 35.13 yuan, with an increase of 0.66%, a turnover rate of 0.78%, a trading volume of 73,500 shares, and a transaction value of 257 million yuan [1]. Group 2: Shareholder Information - As of July 10, 2025, the total number of shareholders for the company was over 40,000 [2][5]. Group 3: Business Operations and Market Presence - The company has established diversified sales channels in the European market, focusing on non-public medical channels through retail pharmacies and partnerships with medical device distributors, which constitute a significant portion of its European sales [3][4]. - The company's overseas business primarily targets Southeast Asia, South America, Western Europe, and the Commonwealth of Independent States, covering over 100 countries and regions globally [6]. Group 4: Capital Flow - On July 18, 2025, the capital flow data indicated a net outflow of 8.87 million yuan from institutional investors, while retail investors showed a net inflow of 10.35 million yuan [7][8].